Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iraq Healthcare Wire.
Press releases published on September 2, 2025
BioStem Technologies to Present at Two Upcoming Investor Conferences
GlobeNewswire
·
September 2, 2025
POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced …
PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE® for Patients with Wagner 1 Diabetic Foot Ulcers
GlobeNewswire
·
September 2, 2025
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy, today announced the launch …
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity …
Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system …
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
GlobeNewswire
·
September 2, 2025
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or …
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
GlobeNewswire
·
September 2, 2025
PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R…
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
GlobeNewswire
·
September 2, 2025
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
September 2, 2025
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, …
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
GlobeNewswire
·
September 2, 2025
THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was …
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
GlobeNewswire
·
September 2, 2025
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today …
Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
GlobeNewswire
·
September 2, 2025
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), ("Hydreight" or the " …
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
GlobeNewswire
·
September 2, 2025
DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced …
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
GlobeNewswire
·
September 2, 2025
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world’s first procedures using MAGiC …
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
GlobeNewswire
·
September 2, 2025
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions
GlobeNewswire
·
September 2, 2025
HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 2, 2025
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be available on …
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
GlobeNewswire
·
September 2, 2025
BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert …
Nkarta to Participate in a September Investor Conference
GlobeNewswire
·
September 2, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor …
Coag-Sense® PT/INR Monitoring System Approved for Patient Self-Testing in Europe
GlobeNewswire
·
September 2, 2025
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense® PT/INR Monitoring System for patient self-testing in Europe. The …
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
GlobeNewswire
·
September 2, 2025
Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for dencatistat, a first-in-class, highly selective …